Request Trial
dmitryintag
dmitryintag / iStockphoto.com
30 August 2017AmericasWenhua Yu, Stephen Maebius and Tianran Yan

Data analysis: the highs and lows of generic-filed IPRs

We reviewed a sub-group of 204 inter partes reviews (IPRs) filed by generic drug companies against pharmaceutical patents to assess Patent Trial and Appeal Board (PTAB) outcomes and key trends in dealing with this technology field. The study captured IPR filings by 14 of the most active generic petitioners among the world’s top-20 generic drug companies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
10 July 2026   Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.
Americas
Exelixis opens two-front patent dispute over Cabometyx copies
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Americas
LSD trade secrets suit over clinical trail info thrown out by judge
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Biotech
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen
Exelixis opens two-front patent dispute over Cabometyx copies
BioNTech and Pfizer secure big European win over mRNA patent
Influential Women in IP 2026: Who made the list?
WilmerHale trade secrets expert moves to new firm
UPC revives patent, but timing sinks Guardant’s appeal
LSD trade secrets suit over clinical trail info thrown out by judge
HGF expands European offering with pair of in-house hires